BioSpace News Archive

Sana Biotechnology, Inc. (NASDAQ: SANA) today announced the publication in Blood of an abstract providing initial clinical data from the first patient treated at the lowest dose in the ongoing ARDENT Phase 1 clinical trial with SC291, a hypoimmune (HIP)-modified allogeneic CD19-directed CAR T cell therapy.

Syndax Pharmaceuticals announced that on December 1, 2023 the Company granted inducement awards to purchase up to 158,000 shares of common stock to nine new employees under the Company’s 2023 Inducement Plan.

NeuroPace, Inc. today announced that the Company will have a substantial presence at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orlando, Florida and virtually from December 1-5, 2023.

Kazia Therapeutics Limited today announced that it has entered into a definitive agreement for the purchase and sale of up to an aggregate of 4,444,445 of the Company’s American Depositary Shares.

Daiichi Sankyo (TSE: 4568) will present new clinical research across its oncology portfolio in multiple types of solid and blood cancers at the 2023 ESMO Asia Congress (#ESMOAsia23), San Antonio Breast Cancer Symposium (#SABCS23) and American Society of Hematology (#ASH23) Annual Meeting prior to its annual R&D Day.

Amneal Pharmaceuticals, Inc. and Strides Pharma Science Limited announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®.

Thermo Fisher Scientific Extends the Expiration of Tender Offer for All Outstanding Common Shares and ADSs of Olink.

Palvella Therapeutics, Inc. today announced the expansion of their strategic partnership to accelerate Phase 3 development of QTORIN™ rapamycin for the treatment of Microcystic Lymphatic Malformations (Microcystic LMs).

Allogene Therapeutics, Inc. today announced that it will participate in one upcoming investor conference in December.

GeneDx today announced new data to be presented at the American Epilepsy Society (AES) annual meeting in Orlando, Florida, December 1-5, 2023, that supports the use of exome sequencing as a first-tier test for patients with epilepsy.